CardioDx Announces Final Endpoint Results from the PRESET Registry at the AHA Scientific Sessions 2016 - Seite 2
The poster presentation, Primary Endpoint Results from a Community-Based Registry Evaluating the Use of a Blood-Based Age/Sex/Gene Expression Test in Patients Presenting with Symptoms Suggestive of Obstructive Coronary Artery Disease reported results from the PRESET Registry, which included 566 stable, non-acute and non-diabetic adult patients without a history of obstructive CAD from 21 primary care practices from September 2012 to August 2014. This final endpoint analysis evaluated both clinical decision-making and one-year safety follow-up among non-acute adult patients with typical or atypical symptoms suggestive of obstructive CAD.
"Wider use of more effective approaches for the management of patients presenting with stable symptoms of coronary artery disease have been needed for some time," said Mark Monane, M.D., FACP, Chief Medical Officer of CardioDx. "The large number of community-based practices included in the PRESET Registry helped demonstrate the generalizability of Corus CAD in this setting. The final endpoint analysis with one-year follow-up post Corus CAD testing reinforces the fact that patients with low scores are unlikely to have major adverse cardiac events and revascularizations and thus helps to provide further confidence to clinicians for integrating Corus CAD into their primary care practices."
About Obstructive Coronary Artery Disease
Coronary artery disease (CAD) is a very common heart condition in the United States. One in seven deaths among Americans is caused
by CAD.2 CAD can cause a narrowing or blockage of the coronary arteries (vessels to the heart that supply the heart with blood, oxygen, and nutrients), reducing blood flow to the
heart muscle. This narrowing or blockage in the coronary arteries is often referred to as obstructive CAD, characterized by the presence of atherosclerosis, or plaque.
Lesen Sie auch
About the Corus CAD Test
Corus CAD is the first and only commercially available blood test that can safely and conveniently help primary care clinicians and cardiologists
assess whether or not a stable non-diabetic patient's symptoms may be due to obstructive coronary artery disease. The test incorporates age, sex and gene expression measurements into a single score
that indicates the likelihood of obstructive CAD. Clinicians use the Corus CAD score, along with other clinical information, to determine whether further cardiac testing is necessary, which can
help patients avoid unnecessary exposure to radiation associated with medical imaging testing, as well as possible reactions to imaging dyes and/or potential complications from invasive cardiac
tests requiring catheterization. The test involves a routine blood draw that is conveniently administered in the clinician's office. The Corus CAD test is the only sex-specific test for the
evaluation of obstructive CAD because it accounts for cardiovascular differences between men and women.